Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LESTAURTINIB: 80 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
80
Total FAERS Reports
12 (15.0%)
Deaths Reported
66
Hospitalizations
80
As Primary/Secondary Suspect
23
Life-Threatening

First Report: 20111224 · Latest Report: 20150823

What Are the Most Common LESTAURTINIB Side Effects?

#1 Most Reported
Febrile neutropenia
23 reports (28.7%)
#2 Most Reported
Hypertriglyceridaemia
13 reports (16.3%)
#3 Most Reported
Diarrhoea
10 reports (12.5%)

All LESTAURTINIB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Febrile neutropenia 23 28.8% 0 23
Hypertriglyceridaemia 13 16.3% 10 5
Clostridium difficile colitis 10 12.5% 0 10
Death 10 12.5% 10 5
Diarrhoea 10 12.5% 0 10
Enterococcal infection 9 11.3% 0 9
Sepsis 9 11.3% 0 9
Bronchiolitis 8 10.0% 0 8
Candida infection 8 10.0% 0 8
Hypertension 8 10.0% 0 8
Klebsiella infection 8 10.0% 0 8
Otitis externa 8 10.0% 0 8
Pulmonary oedema 8 10.0% 0 8
Septic shock 8 10.0% 0 8
Vomiting 8 10.0% 0 8
Corona virus infection 7 8.8% 0 7
Erythema multiforme 7 8.8% 0 7
Feeding intolerance 7 8.8% 0 7
Skin necrosis 7 8.8% 0 7
Staphylococcal infection 7 8.8% 0 7

Who Reports LESTAURTINIB Side Effects? Age & Gender Data

Gender: 61.4% female, 38.6% male. Average age: 1.0 years. Most reports from: US. View detailed demographics →

Is LESTAURTINIB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2011 1 0 1
2013 8 0 8
2014 38 2 36
2015 5 0 4

View full timeline →

What Is LESTAURTINIB Used For?

IndicationReports
Acute lymphocytic leukaemia 64
B precursor type acute leukaemia 5

Official FDA Label for LESTAURTINIB

Official prescribing information from the FDA-approved drug label.